Pharma BD Deal Intelligence
Kinetix is one of the real innovators in the emerging field of protein kinase inhibition. We have made great strides with our existing small molecule program,…
Biotech giant Amgen has agreed to buy privately held Kinetix Pharmaceuticals (Medford, MA) for $170 million. The acquisition of Kinetix will provide Amgen with…
Novartis' imatinib approval for CML in May 2001 triggered an industry-wide arms race for kinase-inhibitor platforms, retroactively validating Amgen's Kinetix…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Amgen acquired privately-held Kinetix Pharmaceuticals (Massachusetts) in an all-stock transaction valued at ~$170M. Brought small-molecule kinase-inhibitor discovery capability complementing Amgen's biologics-heavy portfolio; oncology and inflammation focus.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Kinetix Pharmaceuticals Inc. (this deal) | 2000 | $170M | 39 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
← Browse all deals · How we score deals
More: 2000 deals · Amgen Inc. deals · Immunology deals